Related references
Note: Only part of the references are listed.A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Lucas C. M. Arruda et al.
HAEMATOLOGICA (2022)
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Qi Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Pau Montesinos et al.
LEUKEMIA (2021)
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults
Benjamin H. Goldenson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development
Yiyi Yao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells
S. S. Hoepner et al.
NATURE COMMUNICATIONS (2021)
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Nadia El Khawanky et al.
NATURE COMMUNICATIONS (2021)
Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia
Chiqi Chen et al.
SCIENCE ADVANCES (2021)
Very long chain fatty acid metabolism is required in acute myeloid leukemia
Matthew Tcheng et al.
BLOOD (2021)
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities
Eimear O'Reilly et al.
BLOOD REVIEWS (2021)
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Hagop M. Kantarjian et al.
CANCER (2021)
Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Hui Zhang et al.
CLINICAL CANCER RESEARCH (2021)
Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities
Tony Marchand et al.
FRONTIERS IN IMMUNOLOGY (2021)
Harnessing the Metabolic Vulnerabilities of Leukemia Stem Cells to Eradicate Acute Myeloid Leukemia
Bijender Kumar
FRONTIERS IN ONCOLOGY (2021)
Hematopoietic Cell Kinase (HCK) Is a Player of the Crosstalk Between Hematopoietic Cells and Bone Marrow Niche Through CXCL12/CXCR4 Axis
Fernanda Marconi Roversi et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
JAK-STAT in Early Hematopoiesis and Leukemia
Eirini Sofia Fasouli et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues
Xiaobing Yu et al.
BLOOD (2021)
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Gautam Borthakur et al.
BLOOD CANCER JOURNAL (2021)
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group
Jelena Bila et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote Differentiation
Stephanie Z. Xie et al.
BLOOD CANCER DISCOVERY (2021)
HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia
Wei Zhou et al.
HEMATOLOGY (2021)
Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
Yoko Tabe et al.
FRONTIERS IN ONCOLOGY (2020)
The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
Elisabet Cuyas et al.
AGING-US (2020)
Targeting of cancer stem cells by differentiation therapy
Yoshimi Arima et al.
CANCER SCIENCE (2020)
Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy
Yongfeng Chen et al.
CELL DEATH & DISEASE (2020)
Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia
Heejoo Han et al.
LEUKEMIA & LYMPHOMA (2020)
Phase 1 study of combinatorial sorafenib,G-CSF, and plerixafor treatment in relapsed/refractory,FLT3-ITD-mutated acute myelogenous leukemia patients
Gautam Borthakur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling
Shruti Daga et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
CD123 as a Therapeutic Target Against Malignant Stem Cells
Mayumi Sugita et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia
Wen-Tao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Characterization of a Novel FLT3 BITE Molecule for the Treatment of Acute Myeloid Leukemia
Bettina Brauchle et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells
Courtney L. Jones et al.
CELL STEM CELL (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-in-Human Phase I Study of ladademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
Olga Salamero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Rui Liu et al.
CELL DEATH & DISEASE (2020)
Resveratrol alleviates the interleukin-1β-induced chondrocytes injury through the NF-κB signaling pathway
Hong Yi et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2020)
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
Brett M. Stevens et al.
NATURE CANCER (2020)
Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans
Franziska M. Uhl et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Masayuki Yamashita et al.
NATURE REVIEWS CANCER (2020)
ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+-signalling dysregulation or toxicity in pancreatic acinar cells
Monika A. Jakubowska et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells
Marius Bill et al.
LEUKEMIA (2019)
Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism
Germana Castelli et al.
CANCERS (2019)
Venetoclax-based therapies for acute myeloid leukemia
Veronica A. Guerra et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Emiliano Panieri et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
Benjamin K. Tomlinson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance
Morgane Gourvest et al.
CANCERS (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes
Kimberly N. Smitheman et al.
HAEMATOLOGICA (2019)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Courtney L. Jones et al.
CANCER CELL (2018)
The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia
David B. Sykes
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
IDH1: Linking Metabolism and Epigenetics
Silvia Raineri et al.
FRONTIERS IN GENETICS (2018)
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors
Rita Assi et al.
CURRENT OPINION IN HEMATOLOGY (2018)
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
L. Quotti Tubi et al.
LEUKEMIA (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Preferential association with ClC-3 permits sorting of ClC-4 into endosomal compartments
Raul E. Guzman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Therapeutic targeting of acute myeloid leukemia stem cells
Daniel A. Pollyea et al.
BLOOD (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
X. Xue et al.
ONCOGENE (2016)
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia
David B. Sykes et al.
CELL (2016)
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Norbert Vey et al.
ONCOTARGET (2016)
Upregulation of p27 cyclin-dependent kinase inhibitor and a C-terminus truncated form of p27 contributes to G1 phase arrest
Takayuki Satoh et al.
SCIENTIFIC REPORTS (2016)
MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
Yansong Bian et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2015)
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities
Chandrima Sinha et al.
SEMINARS IN HEMATOLOGY (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
George S. Laszlo et al.
BLOOD (2014)
The variety of leukemic stem cells in myeloid malignancy
D. H. Wiseman et al.
ONCOGENE (2014)
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
Juliette Lambert et al.
ONCOTARGET (2014)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Tobias Neff et al.
BLOOD (2013)
STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2
Winnie F. Tam et al.
CANCER RESEARCH (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Notch pathway activation targets AML-initiating cell homeostasis and differentiation
Camille Lobry et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
R. Majeti
ONCOGENE (2011)
Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer
Veronique Maguer-Satta et al.
STEM CELLS (2011)
A role for DOT1L in MLL-rearranged leukemias
Kathrin M. Bernt et al.
EPIGENOMICS (2011)
Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
Yoriko Saito et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells
Dominik Fuchs et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
The reverse Warburg effect Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Stephanos Pavlides et al.
CELL CYCLE (2009)
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche
Cristina Lo Celso et al.
NATURE (2009)
Detection of functional haematopoietic stem cell niche using real-time imaging
Yucai Xie et al.
NATURE (2009)
The NF-κB Family of Transcription Factors and Its Regulation
Andrea Oeckinghaus et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
W-C Chou et al.
LEUKEMIA (2007)
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Liqing Jin et al.
NATURE MEDICINE (2006)
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
Andrei V. Krivtsov et al.
NATURE (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
A van Rhenen et al.
CLINICAL CANCER RESEARCH (2005)
CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice
S Tavor et al.
CANCER RESEARCH (2004)
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche
F Arai et al.
CELL (2004)
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
KJ Hope et al.
NATURE IMMUNOLOGY (2004)
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis
ST Avecilla et al.
NATURE MEDICINE (2004)
Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
U Testa et al.
BLOOD (2002)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Share Paper
